Phase 3 study of intensive chemotherapy with or without dasatinib in core-binding factor acute myeloid leukemia.
Blood
View this publicationBlood
View this publicationPloS one
View this publicationBlood cancer journal
View this publicationBrain, behavior, and immunity
View this publicationNature immunology
View this publicationCell reports. Medicine
View this publicationFrontiers in immunology
View this publicationJournal of medicinal chemistry
View this publicationMethods in molecular biology (Clifton, N.J.)
View this publicationScience advances
View this publication